Published on
June 23, 2020
- 11:30 GMT
Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women ...
Co-primary endpoints met with response rates of 74.5% for dysmenorrhea (menstrual pain) and 58.5% for non-menstrual pelvic pain (p-values < 0.0001) Women receiving relugolix combination therapy, on average, had a 73.3% reduction on the Numerical Rating …
Distribution channels:
Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry
...
